Abbott study finds Type 2 Diabetes patients using GLP-1 medicines and FreeStyle Libre technology together significantly reduce HbA1c levels by 2.4%.

Abbott Lab's study shows that using GLP-1 medicines and FreeStyle Libre technology together significantly improved Type 2 Diabetes patients' HbA1c levels, reducing them by 2.4% compared to 1.7% when using GLP-1 alone. The study findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes. Abbott's stock is currently up 0.63% on the New York Stock Exchange.

March 06, 2024
4 Articles